Arivin Therapeutics
Small molecules against high-priority Gram-negative pathogens (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae) with a dual mechanism — neutralising bacterial toxins and disrupting biofilm formation — an anti-virulence approach to antibiotic resistance. Spin-off of Aalto University and the University of Helsinki (2022), based on discoveries published in Nature Communications.
The row
- Stage
- Pre-revenue — No sales yet
- Location
- Helsinki
- Founded
- 2022
- Research origin
- Aalto + Univ. of Helsinki
- Business ID
- 3331690-9 · Finnish trade register
- Funding
- €3M seed (9/2025, incl. Business Finland Venture Capital)
Links
Where this sits on the map
Arivin Therapeutics is one of 33 companies in Therapeutics & Diagnostics. The others:
How this row was decided
Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗